Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Hybrid Adeno-Retroviral Vector for the Transformation of Cells (E-258-1998)
Case ID:
TAB-901
Web Published:
12/6/2022
The invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation, either in vivo or in vitro. The hybrid vectors have an adenoviral backbone with retroviral long terminal repeats (LTRs). Such vectors are capable of transforming dividing or non-dividing cells and integrate stably into the chromosome providing a means of efficient, reliable, long-term gene expression. The vector was packaged as a recombinant adenovirus and delivered to the target cell. Unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest, and retroviral structural proteins are not required.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Hybrid_Adeno-Retroviral_Vect or_for_the_Transformation_of_Cells_(E-258-1998)
Keywords:
Adeno-Retroviral
Chimeric Vector
Duke DNA Project
GB2A2X
GB2AXX
GB2XXX
GBXXXX
GENE THERAPY
GXXXXX
hybrid vector
Vector
viral vector
Bookmark this page
Download as PDF
For Information, Contact:
Vladimir Knezevic
Senior Advisor for Commercial Evaluations
NIH Technology Transfer
vlado.knezevic@nih.gov